Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Signs Two Deals to Accelerate Commercialization of DNA Profiling Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IntegenX separately announced deals with Caliper Life Sciences and SoftGenetics to build out the capabilities of its DNA profiling platform.

In its deal with Caliper, IntegenX gains access to Caliper's microfluidics patent portfolio. It will leverage its Move technology and Caliper's intellectual patent estate in order to accelerate commercialization of the Apollo 200 RapidHit DNA Profiling System being developed by IntegenX for the automated production of standardized DNA profiles.

Profiles generated on the system can then be used to match existing DNA records in domestic and international databases, or expand those databases, IntegenX said.

The Apollo 200 System is being developed for use by law enforcement agencies in the US Departments of Defense and Homeland Security, and reduces the time to produce a standard human identification DNA profile to less than two hours, compared to the 15 hours it now takes with other technologies.

In a statement, Stevan Jovanovic, president and CEO of IntegenX, said the deal "supports our 'sample-to-answer' strategy and enables us to build upon IntegenX's core strengths in product development and integration."

Separately, the Pleasanton, Calif.-base company said that SoftGenetics will provide its GeneMarker HID forensics software to power the data analysis feature on the Apollo 200 System. The software will allow the platform to generate unique human DNA profiles in standardized formats compatible with human identification database search systems.

Incorporation of the software into the Apollo 200 platform will automate and hasten the production of "critical information for border security operations, crime scene analysis, paternity and other kinship determinations, and other human identification needs," IntegenX said.

Use of SoftGenetics software, "will enable us to greatly expand the utility of DNA detection for both existing and new applications," Jovanovich said.

Financial and other terms of the two deals were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.